Robert A. Conerly Named C.F.O. of Rib-X Pharmaceuticals, Inc.
New Haven, Connecticut. June 18, 2002 — Rib-X Pharmaceuticals, Inc.,
a privately held bioscience company focused on the discovery of new
anti-infectives, today announced that Robert A. Conerly has been
appointed to the newly created position of Chief Financial Officer
and Vice President of Finance.
Mr. Conerly joins Rib-X from Pharmion Corporation in Boulder, Colorado, where as Chief Financial Officer and Vice President of Finance, he led the specialty pharmaceutical company through a $65 million private equity financing in November, 2001. Prior to Pharmion, Mr. Conerly spent six years at AstraZeneca P.L.C., both in the U.S. and Europe, in numerous financial positions. As Director of Business Performance for the newly merged AstraZeneca, he led senior management in the development and monitoring of performance objectives. Mr. Conerly began his professional career at Price Waterhouse, where he advanced to Senior Manager and worked in Audit Advisory Services, the Entrepreneurial Services Center, and the Mergers and Acquisitions Group.
"Rib-X is firmly on its way to discovering a new class of antibiotics, and to achieve this goal we are bringing the best talent together to form our multidisciplinary team," said Dr. Susan Froshauer, the President and Chief Executive Officer of Rib-X. "We are pleased to have someone of Bob's caliber on board with us and have every confidence that Bob's experience, encompassing an early stage company, a major pharmaceutical entity, and one of the world's leading accounting firms, will prove to be a major asset going forward."
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product-driven small-molecule drug discovery and development company focused on developing and commercializing antibiotics to treat highly-resistant bacterial infections. Based in New Haven, Connecticut, the Company has raised over $170 million and has two programs, delafloxacin and radezolid, in advanced clinical trials. In addition, a preclinical program featuring an entirely new class of broad-spectrum antibiotics with the potential to treat even highly- resistant Gram-negative infections is scheduled to begin clinical trials in 2011.
Rib-X designs and develops novel small-molecule antibiotics by leveraging the Company's Nobel Prize- winning discovery platform to perform structure-based design and optimization. While many commercially valuable classes of antibiotics bind to the bacterial ribosome, including oxazolidinones, tetracyclines and macrolides, traditional antibiotic discovery relies heavily on serendipity. Rib-X's key competitive advantage is its proprietary understanding of ribosome structure, which enables it to generate antibiotics that overcome known resistance mechanisms and have broad-spectrum activity.
Rib-X's integrated research strategy combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, thereby allowing Rib-X to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinct new antibiotic classes.
Mr. Conerly joins Rib-X from Pharmion Corporation in Boulder, Colorado, where as Chief Financial Officer and Vice President of Finance, he led the specialty pharmaceutical company through a $65 million private equity financing in November, 2001. Prior to Pharmion, Mr. Conerly spent six years at AstraZeneca P.L.C., both in the U.S. and Europe, in numerous financial positions. As Director of Business Performance for the newly merged AstraZeneca, he led senior management in the development and monitoring of performance objectives. Mr. Conerly began his professional career at Price Waterhouse, where he advanced to Senior Manager and worked in Audit Advisory Services, the Entrepreneurial Services Center, and the Mergers and Acquisitions Group.
"Rib-X is firmly on its way to discovering a new class of antibiotics, and to achieve this goal we are bringing the best talent together to form our multidisciplinary team," said Dr. Susan Froshauer, the President and Chief Executive Officer of Rib-X. "We are pleased to have someone of Bob's caliber on board with us and have every confidence that Bob's experience, encompassing an early stage company, a major pharmaceutical entity, and one of the world's leading accounting firms, will prove to be a major asset going forward."
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product-driven small-molecule drug discovery and development company focused on developing and commercializing antibiotics to treat highly-resistant bacterial infections. Based in New Haven, Connecticut, the Company has raised over $170 million and has two programs, delafloxacin and radezolid, in advanced clinical trials. In addition, a preclinical program featuring an entirely new class of broad-spectrum antibiotics with the potential to treat even highly- resistant Gram-negative infections is scheduled to begin clinical trials in 2011.
Rib-X designs and develops novel small-molecule antibiotics by leveraging the Company's Nobel Prize- winning discovery platform to perform structure-based design and optimization. While many commercially valuable classes of antibiotics bind to the bacterial ribosome, including oxazolidinones, tetracyclines and macrolides, traditional antibiotic discovery relies heavily on serendipity. Rib-X's key competitive advantage is its proprietary understanding of ribosome structure, which enables it to generate antibiotics that overcome known resistance mechanisms and have broad-spectrum activity.
Rib-X's integrated research strategy combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, thereby allowing Rib-X to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinct new antibiotic classes.
| Public Relations |
|---|
|
Kari Watson
MacDougall BioMedical Communications 781-235-3060 kari@macbiocom.com |
| Investor Relations |
|
Sarah Cavanaugh
MacDougall BioMedical Communications 781-235-3060 scavanaugh@macbiocom.com |